{
    "id": 28317,
    "fullName": "YES1 act mut",
    "impact": "unknown",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "YES1 act mut indicates that this variant results in a gain of function in the Yes1 protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 7525,
        "geneSymbol": "YES1",
        "terms": [
            "YES1",
            "c-yes",
            "HsT441",
            "P61-YES",
            "Yes"
        ]
    },
    "variant": "act mut",
    "createDate": "06/14/2018",
    "updateDate": "10/02/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14142,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Gilotrif (afatinib) and Sprycel (dasatinib) in culture, resulting in decreased AKT and ERK phosphorylation and reduced cell viability (PMID: 29875142).",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 1351,
                "therapyName": "Afatinib + Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14152,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Tagrisso (osimertinib) and Sprycel (dasatinib) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142)",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14141,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Gilotrif (afatinib) and Saracatinib (AZD0530) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 7028,
                "therapyName": "Afatinib + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14139,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, were associated with resistance to Gilotrif (afatinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14138,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, were associated with resistance to Tarceva (erlotinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14140,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, were associated with resistance to Tagrisso (osimertinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29949,
            "profileName": "EGFR exon 19 del YES1 act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33484,
            "profileName": "YES1 act mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}